Arana completes Phase II
Monday, 09 March, 2009
Arana Therapeutics, currently the subject of a takeover bid by US company Cephalon, has completed its Phase II trial of lead candidate ART621 in psoriasis.
The trial met the primary endpoints of tolerability and safety. Secondary findings included evidence of anti-tumour necrosis factor activity, a reduction in severity in some patients and no antibody responses against the drug, suggesting the drug has low immunogenicity, the company said.
ART621 is a human domain-based antibody directed against TNF. It is currently in two Phase II trials for rheumatoid arthritis in combination with methotrexate.
The study was conducted at the Nucleus Network in Melbourne and CMAX in Adelaide.
Scientists uncover how cancer cells hide from immune system
By targeting the RNA helicase known as DDX6, scientists could enable the immune system to...
Vanillin flavouring in vapes may disrupt embryo development
Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
